Technical analysis of AN2 Therapeutics, Inc. (ANTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
Price Performance
| 1 month | -11.06% |
| 3 months | +6.20% |
| Year-to-date | +365.79% |
| 1 year | +311.63% |
| 3 years | -62.61% |
52-Week Range
| 52-week High | $7.19 |
| 52-week Low | $1.00 |
| Avg Volume (90d) | 266K |
Technical Indicators
| SMA 50 | $5.43 |
| SMA 200 | $3.54 |
| Beta | -1.32 |
| 30-day Volatility (annualised) | 49.9% |
| Price vs SMA 50 | -2.1% |
| Price vs SMA 200 | +50.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.23 | |
| 2025-11 | $1.09 | -11.4% |
| 2025-12 | $1.14 | +4.6% |
| 2026-01 | $1.13 | -0.9% |
| 2026-02 | $1.10 | -2.7% |
| 2026-03 | $3.42 | +210.9% |
| 2026-04 | $4.55 | +33.0% |
| 2026-05 | $4.33 | -4.8% |
| 2026-06 | $4.84 | +11.8% |
| 2026-07 | $5.35 | +10.5% |
| 2026-08 | $5.55 | +3.7% |
| 2026-09 | $5.31 | -4.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | $-0.05 | $8M |
| 2026-09-14 | | |
Price
| Price | $5.34 |
| Market Cap | $192M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.15 |
| EV / EBITDA | -3.96 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 14.32 |